Thomas H. Kean
Trade Performance Intelligence
Score: 4/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
5 flagsRep. Thomas H. Kean bought $1,001 - $15,000 in $ABT on 2025-07-21 — 45 days before HR5127 ("PrEP and PEP are Prevention Act") was introduced, a bill that could increase demand for related medical products.
Rep. Thomas H. Kean bought $1,001 - $15,000 in $ABT on 2025-07-21 — 58 days before HR5343 ("Ensuring Patient Access to Critical Breakthrough Products Act") advanced out of committee, indicating significant legislative momentum.
Rep. Thomas H. Kean sold $15,001 - $50,000 in $JNJ on 2025-07-31 — 50 days before HR5526 ("Biosimilar Red Tape Elimination Act") was introduced, a bill that could reduce market exclusivity for some pharmaceutical products.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $CHKP | Check Point Software Technologies Ltd. - Ordinary Shares | $15K-$50K | — | — | — | Jul 29, 2025 |
| BUY | $ABT | Abbott Laboratories Common Stock | $1K-$15K | — | — | — | Jul 21, 2025 |
| PARTIAL SELL | $JNJ | Johnson & Johnson Common Stock | $15K-$50K | — | — | — | Jul 31, 2025 |
| PARTIAL SELL | $SYK | Stryker Corporation Common Stock | $15K-$50K | — | — | — | Jul 31, 2025 |
| SELL | $ADBE | Adobe Inc. - Common Stock | $1K-$15K | — | — | — | Jul 29, 2025 |
| EXCHANGE | $LBRDK | Liberty Broadband Corporation - Class C Common Stock | $1K-$15K | — | — | — | Jul 15, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
PrEP and PEP are Prevention Act
The PrEP and PEP are Prevention Act mandates no-cost coverage for HIV prevention drugs and related services, directly increasing demand for these medications and associated diagnostic tests. This legislation creates a guaranteed market expansion for pharmaceutical companies producing PrEP/PEP drugs and diagnostic providers, while increasing costs for health insurers.
Biosimilar Red Tape Elimination Act
The Biosimilar Red Tape Elimination Act, HR5526, if enacted, would automatically grant interchangeability to biosimilar products, reducing market exclusivity for innovator biologic manufacturers. This bill is in the early stages, having been referred to the House Committee on Energy and Commerce on September 19, 2025. Innovator biologic manufacturers like Amgen, Johnson & Johnson, and Biogen face potential market share erosion, while biosimilar producers like Viatris and Teva could benefit.
AI-Related Job Impacts Clarity Act
The AI-Related Job Impacts Clarity Act, S3108, mandates quarterly disclosures on AI-related job changes, increasing compliance burdens and operational costs for companies heavily invested in AI. This bill, currently in the early stages of committee referral, introduces new data transparency risks for investors in AI-centric firms. Companies across all sectors utilizing AI for automation or workforce changes face direct reporting requirements.
End the Vaccine Carveout Act
The 'End the Vaccine Carveout Act' removes liability protections for vaccine manufacturers, directly increasing their legal and operational risks. This bill, if enacted, will significantly alter the risk profile and profitability of pharmaceutical companies producing vaccines. Companies like Pfizer, Moderna, GSK, and Johnson & Johnson face increased litigation exposure.
To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.
HR5917 authorizes the President to grant normal trade relations (NTR) status to most countries, excluding Belarus, Cuba, and North Korea, by waiving the Jackson-Vanik amendment. This action reduces tariffs and trade barriers for goods from these countries, directly benefiting U.S. importers and consumers through lower costs. Companies relying on global supply chains will see improved margins and increased access to goods.
Price Gouging Prevention Act of 2025
The Price Gouging Prevention Act of 2025 directly limits corporate profitability for large-cap companies during 'exceptional market shock' events by mandating pre-shock margin maintenance. This legislation increases regulatory risk and caps potential upside for companies with significant market power across all sectors, leading to decreased profitability during crises. All major corporations face reduced profit potential and increased compliance costs.
Protecting Free Vaccines Act of 2025
The 'Protecting Free Vaccines Act of 2025' (S.2857) is in the early stages, having been referred to committee. This bill aims to codify existing mandates for ACIP-recommended immunization coverage, ensuring stable revenue for vaccine manufacturers and health insurers by preventing future disruptions to current vaccine coverage. It does not introduce new market drivers or significant changes to demand.
Protecting Free Vaccines Act
The 'Protecting Free Vaccines Act' (HR5448) is an early-stage bill that, if enacted, would mandate no-cost coverage for ACIP-recommended vaccines by Medicare, Medicaid, CHIP, and private insurers until January 1, 2030. This would directly increase demand for vaccine manufacturers and shift cost burdens to health insurers and government programs. Vaccine manufacturers are positioned for sustained revenue growth, while health insurers face increased costs.
Ensuring Patient Access to Critical Breakthrough Products Act
The 'Ensuring Patient Access to Critical Breakthrough Products Act' (HR5343) has advanced out of committee, indicating significant legislative momentum for expedited Medicare coverage of FDA-designated breakthrough medical devices. This bill directly benefits manufacturers by removing a key barrier to market adoption and revenue generation. Companies like Medtronic, Intuitive Surgical, Abbott Laboratories, Johnson & Johnson, and Becton, Dickinson and Company are positioned to gain from this accelerated market access.
Medical Device Nonvisual Accessibility Act of 2025
The Medical Device Nonvisual Accessibility Act of 2025 (HR5605) has been introduced in the House and referred to the Committee on Energy and Commerce. This bill mandates nonvisual accessibility standards for medical devices with digital interfaces, creating new compliance requirements for manufacturers while expanding market access to blind and low-vision consumers. There is no explicit funding amount specified in the bill.
Live Charts
Other Filings by Thomas H. Kean
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.